Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease

European Neurology

Volumn 43, Issue 3, 2000, Pages 161-169

  Fukuyama, Ryuichi ^a   Mizuno, Toshiki ^a   Mori, Satoru ^a   Yanagisawa, Katsuhiko ^b   Nakajima, Kenji ^a   Fushiki, Shinji ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cerebrospinal fluid; Electrophoresis, two dimensional; ELISA; Lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; HEPARIN; MANGANESE; MARKER;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; HUMAN; MACROGLIA; NERVE DEGENERATION; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 0034109648     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008157     Document Type: Article

References (41)

1. Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J: The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Rev 1998;27:119-142.
2. Mahley RW: Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
3. Rubinsztein DC: Apolipoprotein: A review of its roles in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Alzheimer's disease. Psychol Med 1995;25:223-229.
4. Wisniewski T, Frangione B: Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-238.
5. Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD: Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:8098-8102.
6. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 1997;17:263-264.
7. Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43: 1467-1472.
8. van Duijin CM, de Knijff P, Crus M, Wehnert A, Havekes LM, Hofman A, Van Broeckhoven C: Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994;7:74-78.
9. Welch WJ, Gambetti P: Chaperoning brain disease. Nature 1998;392:23-24.
10. Mahley RW, Nathan BP, Pitas RE: Apolipoprotein E, structure, function, and possible roles in Alzheimer's disease. Ann NY Acad Sci 1996;777:139-145.
11. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J: Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Association with high density lipoproteins. Biochem Biophys Res Commun 1996;223:592-597.
12. Bullido MJ, Artiga MJ, Recucro M, Sastre I, Garcia MA, Aldudo J, London C, Han SW, Morris HC, Frank A, Vazquez J, Goate A, Valdivieso F: A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 1998;18:69-71.
13. Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, März W, Wahlund L-O, Cowburn RF: Cerebrospinal fluid apolipoprotein E levels in Alzheimer's disease patients are increased at follow-up and show a correlation with levels of tau protein. Neurosci Lett 1997;229:85-88.
14. Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G: Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci 1997;145:33-39.
15. Terrisse L, Poirier J, Bertrand P, Merched A, Visvikis S, Siest G, Milne R, Rassart E: Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's disease patients. J Neurochem 1998;71:1643-1650.
16. Blennow K, Hesse C, Fredman P: Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport 1994;5:2534-2536.
17. Ladén M, Hesse C, Fredman P, Regland B, Wallin A, Blennow K: Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Dementia 1995;7:273-278.
18. Lehtimäki T, Pirttilä T, Mehta PD, Wisniewski HM, Frey H, Nikkari T: Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the Cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet 1995;95:39-42.
19. Hahne S, Nordstedt C, Åhlin A, Nybäck H: Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci Lett 1997;224:99-102.
20. Lefranc D, Vermersch P, Dallongeville J, Daemes-Monpeurt C, Petit H, Delacourte A: Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci Lett 1996;212:91-94.
21. Rösler N, Wichart I, Bancher C, Jellinger KA: Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: Impact on non-Alzheimer's dementia? J Neurol Transm 1996; 47:259-266.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944.
23. Fukuyama R, Brady D, Rapoport SI: Development and application of a modified hybridoma technique for isolating monoclonal antibodies to human brain regions. J Neurosci Methods 1995;59:199-204.
24. Hixson JE, Verner DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31: 545-548.
25. Puchois P, Luley C, Alaupovic P: Comparison of four procedures for separating apolipoprotein A-and apolipoprotein B-containing lipoproteins in plasma. Clin Chem 1987;33:1597-1602.
26. Roheim PS, Carey M, Forte T, Vega GL: Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979;76:4646-4649.
27. Merril CR, Harrington MG: 'Ultrasensitive' silver stains: Their use exemplified in the study of normal human cerebrospinal fluid proteins separated by two-dimensional electrophoresis. Clin Chem 1984;30:1938-1942.
28. Borghini I, Barja F, Pometta D, James RW: Characterization of subpopulation of lipoprotein particles isolated from human cerebrospinal fluid. Biochem Biophys Acta 1995;1255: 192-200.
29. Kunicki S, Richardson J, Metha PD, Kim KS, Zorychta E: The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42. apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin Biochem 1998;31:409-415.
30. Song H, Saito K, Scishima M, Noma A, Urakami K, Nakashima K: Cerebrospinal fluid apo E and A-I concentrations in early-and late-onset Alzheimer's disease. Neurosci Lett 1997; 231:175-178.
31. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel C: Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta 1991;196:167-176.
32. Pitas RE, Boyles JK, Lee SH, Hui D, Weisberger KH: Lipoproteins and their receptors in cerebrospinal fluid and identification of apolipoprotein B.E (LDL) receptors in the brain. J Biol Chem 1987;262:14352-14360.
33. Ohe Y, Ishikawa K, Itoh Z, Tatemoto K: Cultured leptomeningeal cells secrete cerebrospinal fluid proteins. J Neurochem 1996;67:964-971.
34. White L, Petrovitch H, Ross W, Masaki KH, Abbolt RD, Teng EL, Rodriguez BL, Blanchette PL, Havlik RJ, Wergowske G, Chiu D, Foley DJ, Murdaugh C, Curb JD: Prevalence of dementia in older Japanese-American men in Hawaii. JAMA 1996;276:955-960.
35. Poirier J, Hess M, May PC, Finch CE: Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Mol Brain Res 1991;11:97-106.
36. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W, Haase AT: Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 1991;65:4759-4768.
37. Yamada T, Kondon A, Takamatsu J, Tateishi J, Goto I: Apolipoprotein E mRNA in the brain of patients with Alzheimer's disease. J Neurol Sci 1995;129:56-61.
38. Crols R, Sacrons J, Noppe M, Lowenthal I: Increased GFAP levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome. J Neurol 1986;233:157-160.
39. Gunnersen D, Haley B: Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer's disease patients: A potential diagnostic biochemical marker. Proc Natl Acad Sci USA 1992;89:11949-11953.
40. Möckel B, Zinke H, Flach R, Weiss B, Weiler-Güttler H, Gassen HG: Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J Neurochem 1994;62:788-798.
41. Svennerholm L, Gottfries C-G: Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type 1) and demyclination in late-onset form (type II). J Neurochem 1994; 62:1039-1047.